New study compares different approaches for stroke prevention in patients with non-valvular atrial fibrillation

October 25, 2016 by Adam Pope

A recent study from University of Alabama at Birmingham researchers published in PLOS ONE compares different available treatments for stroke prevention in patients with non-valvular atrial fibrillation.

The group identified six with 59,627 patients comparing six different FDA-approved treatment alternatives. The study combined all phase-three randomized controlled clinical trials comparing different novel oral blood thinners, left atrial appendage closure devices, known as WATCHMAN devices, and Coumadin (warfarin) for in patients with non-valvular atrial fibrillation. Investigators reported data on ischemic stroke, major bleeding and primary safety endpoint from these clinical trials.

WATCHMAN left atrial appendage devices are used as an alternative to long-term warfarin therapy for stroke risk-reduction patients with non-valvular atrial fibrillation.

UAB doctors say too many options may not be a good thing.

"The occurrence of multiple treatment pathways has presented dilemmas for the clinicians," said Navkaranbir S. Bajaj, M.D., the first author of the PLOS ONE study who designed and conducted the analyses for the study.

"We exploited the fact that no direct comparisons from trials were available between WATCHMAN and novel oral anti-coagulants," said Bajaj, instructor fellow in the division of .

The study explains that, while direct evidence from is lacking, indirect comparisons using systematic network meta-analyses can provide useful complementary information that may be less biased than the direct evidence.

Researchers have found that all treatments had comparable efficacy in reducing stroke rates. However, Apixaban, one of the novel oral blood thinners, was a clear winner in terms of safety profile, and the WATCHMAN device was ranked last due to a higher number of procedural adverse events.

"In an era of precision medicine, we need to individualize treatment for our patients," said senior author Pankaj Arora, M.D., assistant professor in the Division of Cardiovascular Disease. "Our current analysis gives insight into how one can do that to prevent stroke in patients with atrial fibrillation."

Arora says one size does not fit all, and his clinical translational research group is actively working to apply this order to all cardiovascular diseases. The authors concluded that the trade-off between safety and efficacy should be the driving force, and the hierarchical ranking presented in this paper can serve as a clinical tool to guide selection of therapy in patients with atrial fibrillation.

Explore further: Short episodes of abnormal heart rhythm may not increase risk of stroke

More information: Navkaranbir S. Bajaj et al. Comparison of Approaches for Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation: Network Meta-Analyses of Randomized Controlled Trials, PLOS ONE (2016). DOI: 10.1371/journal.pone.0163608

Related Stories

Short episodes of abnormal heart rhythm may not increase risk of stroke

October 17, 2016
People with pacemakers or defibrillators who experience only short episodes of an abnormal heart rhythm known as atrial fibrillation have a very low risk of stroke, suggesting that anticoagulants in this group of patients ...

How safe and effective are new drugs for stroke prevention?

October 3, 2016
For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is cumbersome, because it requires ongoing blood test to monitor the effect ...

New oral anticoagulants provide same stroke prevention as warfarin but cause less bleeding

August 27, 2016
The new oral anticoagulants provide the same stroke prevention as warfarin but cause less intracranial bleeding, reports an observational study in more than 43 000 patients presented at ESC Congress 2016 today by Dr Laila ...

Alcohol-related hospitalization associated with doubled stroke risk in atrial fibrillation

August 27, 2016
Alcohol related hospitalisation is associated with a doubled risk of ischaemic stroke risk in patients with non-valvular atrial fibrillation, according to a study presented at ESC Congress 2016 today by Dr Faris Al-Khalili, ...

Team demonstrates cost-effectiveness of Watchman device

December 21, 2015
The WATCHMAN Left Atrial Appendage Closure Device is more cost-effective than warfarin and non-warfarin oral anticoagulants (NOACs) for stroke reduction in patients with non-valvular atrial fibrillation, according to a study ...

Societies issue recommendations for left atrial appendage occlusion

June 29, 2015
The American College of Cardiology, Heart Rhythm Society and Society for Cardiovascular Angiography and Interventions today released a new overview on the implantation of left atrial appendage occlusion devices.

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.